Latent and active tuberculosis development in patients with rheumatoid arthritis receiving biologic disease-modifying antirheumatic drugs: A single-center prospective study.
Biologics have revolutionized the treatment of rheumatoid arthritis (RA) in recent years.However, data from clinical trials and actual clinical practice have shown that biologics currently in use may constitute a risk factor for reactivation of tuberculosis (TB) in patients with latent TB infection.Therefore, screening for latent and active TB infe